Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: An open-label randomized controlled trial

Tuberculosis

Volumn 94, Issue 6, 2014, Pages 564-578

  Idoko, Olubukola T ^a   Owolabi, Olumuyiwa A ^a   Owiafe, Patrick K ^a   Moris, Philippe ^b   Odutola, Aderonke ^a   Bollaerts, Anne ^b   Ogundare, Ezra ^a   Jongert, Erik ^b   Demoitié, Marie Ange ^b   Ofori Anyinam, Opokua ^b   Ota, Martin O ^a,c  

^a MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^b GSK   (Belgium)

^c WHO REGIONAL OFFICE FOR AFRICA   (Congo)

Author keywords

AS01; Co administration; EPI; M72; Tuberculosis vaccine

Indexed keywords

BCG VACCINE; DIPHTHERIA PERTUSSIS TETANUS HEPATITIS B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; IMMUNOGLOBULIN G ANTIBODY; M72 AS01 TUBERCULOSIS VACCINE; MENINGITIS VACCINE; MENINGOCOCCUS VACCINE; ORAL POLIOMYELITIS VACCINE; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG; VACCINE; BACTERIUM ANTIBODY; CYTOKINE; IMMUNOGLOBULIN G;

ANTIBODY RESPONSE; ARTICLE; ATOPIC DERMATITIS; BCG VACCINATION; BRAIN MALARIA; BRONCHOPNEUMONIA; BURN; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHILD; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG ERUPTION; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPANDED PROGRAM ON IMMUNIZATION; EYE DISCHARGE; FEMALE; FEVER; FOLLOW UP; FURUNCULOSIS; GAMBIAN; GASTROENTERITIS; GASTROINTESTINAL DISEASE; HEALTH PROGRAM; HEAT RASH; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMPETIGO; INFECTION PREVENTION; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALARIA; MALE; OPEN STUDY; OTITIS MEDIA; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RASH PUSTULAR; RESPIRATORY TRACT INFECTION; SEPSIS; SEPTIC RASH; STAPHYLOCOCCUS INFECTION; SWELLING; TINEA CORPORIS; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; VOMITING; ADVERSE EFFECTS; BIOSYNTHESIS; CLINICAL TRIAL; DOSE RESPONSE; IMMUNIZATION; IMMUNOLOGY; INFANT; PROCEDURES;

ANTIBODIES, BACTERIAL; BCG VACCINE; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; INFANT; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 84919461676     PISSN: 14729792     EISSN: 1873281X     Source Type: Journal    
DOI: 10.1016/j.tube.2014.07.001     Document Type: Article

References (38)

1. G.A. Colditz, C.S. Berkey, F. Mosteller, T.F. Brewer, M.E. Wilson, and E. Burdick The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature Pediatrics 96 1995 29 35
2. World Health Organization Global tuberculosis control: WHO report 2013 2013 WHO/HTM/TB/2013.11:1-289
3. L.C. Rodrigues, S.M. Pereira, S.S. Cunha, B. Genser, M.Y. Ichihara, and S.C. de Brito Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial Lancet 366 2005 1290 1295
4. R.L. Sepulveda, C. Parcha, and R.U. Sorensen Case-control study of the efficacy of BCG immunization against pulmonary tuberculosis in young adults in Santiago, Chile Tuber Lung Dis 73 1992 372 377
5. C.C. Leung, C.M. Tam, S.L. Chan, M. Chan-Yeung, C.K. Chan, and K.C. Chang Efficacy of the BCG revaccination programme in a cohort given BCG vaccination at birth in Hong Kong Int J Tuberc Lung Dis 5 2001 717 723
6. Karonga Prevention Trial Group Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi Lancet 348 1996 17 24
7. World Health Organization Global tuberculosis program and global programme on vaccines: statement on BCG revaccination for the prevention of tuberculosis 1995 229 236
8. + T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial Vaccine 31 2013 2196 2206
9. C.L. Day, M. Tameris, N. Mansoor, M. van Rooyen, M. de Kock, and H. Geldenhuys Induction and regulation of T-cell immunity by the novel TB vaccine M72/AS01 in South African adults Am J Respir Crit Care Med 188 2013 492 502
10. J. Montoya, J.A. Solon, S.R. Cunanan, L. Acosta, A. Bollaerts, and P. Moris A randomized, controlled dose-finding phase II study of the M72/AS01 candidate tuberculosis vaccine in healthy PPD-positive adults J Clin Immunol 33 2013 1360 1375
11. Y.A. Skeiky, M.R. Alderson, P.J. Ovendale, J.A. Guderian, L. Brandt, and D.C. Dillon Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein J Immunol 172 2004 7618 7628
12. D.C. Dillon, M.R. Alderson, C.H. Day, D.M. Lewinsohn, R. Coler, and T. Bement Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family Infect Immun 67 1999 2941 2950
13. Y.A. Skeiky, M.J. Lodes, J.A. Guderian, R. Mohamath, T. Bement, and M.R. Alderson Cloning, expression, and immunological evaluation of two putative secreted serine protease antigens of Mycobacterium tuberculosis Infect Immun 67 1999 3998 4007
14. World Health Organization WHO global database on child growth and malnutrition 1997 http://libdoc.who.int/hq/1997/WHO-NUT-97.4.pdf
15. N. Garçon, P. Chomez, and M. Van Mechelen GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives Expert Rev Vaccines 6 2007 723 739
16. N. Garçon, and M. Van Mechelen Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems Expert Rev Vaccines 10 2011 471 486
17. J. Díez-Domingo, M. Garcés-Sanchez, J.M. Baldó, M.V. Planelles, I. Ubeda, and A. JuBert Immunogenicity and safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase II, randomized, open, controlled study Pediatr Infect Dis J 29 2010 e35 e46
18. E malaria candidate vaccine when integrated in the expanded program of immunization J Infect Dis 202 2010 1076 1087
19. M.O. Ota, A.A. Odutola, P.K. Owiafe, S. Donkor, O.A. Owolabi, and N.J. Brittain Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants Sci Transl Med 3 2011 88ra56
20. A. Marchant, and M. Goldman T cell-mediated immune responses in human newborns: ready to learn? Clin Exp Immunol 141 2005 10 18
21. + T-cell memory responses induced by BCG vaccination of newborns J Infect Dis 207 2013 1084 1094
22. P.E. Fine Variation in protection by BCG: implications of and for heterologous immunity Lancet 346 1995 1339 1345
23. G.F. Black, R.E. Weir, S. Floyd, L. Bliss, D.K. Warndorff, and A.C. Crampin BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies Lancet 359 2002 1393 1401
24. P. Andersen, and T.M. Doherty The success and failure of BCG - implications for a novel tuberculosis vaccine Nat Rev Microbiol 3 2005 656 662
25. L. Brandt, J. Feino Cunha, A. Weinreich Olsen, B. Chilima, P. Hirsch, and R. Appelberg Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis Infect Immun 70 2002 672 678
26. M.O. Ota, J. Vekemans, S.E. Schlegel-Haueter, K. Fielding, M. Sanneh, and M. Kidd Influence of Mycobacterium bovis bacillus Calmette-Guérin on antibody and cytokine responses to human neonatal vaccination J Immunol 168 2002 919 925
27. L. Maródi Innate cellular immune responses in newborns Clin Immunol 118 2006 137 144
28. O. Levy, K.A. Zarember, R.M. Roy, C. Cywes, P.J. Godowski, and M.R. Wessels Selective impairment of TLR-mediated innate immunity in human newborns: neonatal blood plasma reduces monocyte TNF-α induction by bacterial lipopeptides, lipopolysaccharide, and imiquimod, but preserves the response to R-848 J Immunol 173 2004 4627 4634
29. K. Vanden Driessche, A. Persson, B.J. Marais, P.J. Fink, and K.B. Urdahl Immune vulnerability of infants to tuberculosis Clin Dev Immunol 2013 2013 781320
30. K.L. Flanagan, S. Burl, B.L. Lohman-Payne, and M. Plebanski The challenge of assessing infant vaccine responses in resource-poor settings Expert Rev Vaccines 9 2010 665 674
31. H.T. Maecker, A. Rinfret, P. D'Souza, J. Darden, E. Roig, and C. Landry Standardization of cytokine flow cytometry assays BMC Immunol 6 2005 13
32. M.A. Suni, L.J. Picker, and V.C. Maino Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry J Immunol Methods 212 1998 89 98
33. A. Deenadayalan, P. Maddineni, and A. Raja Comparison of whole blood and PBMC assays for T-cell functional analysis BMC Res Notes 6 2013 120
34. D. De Groote, P.F. Zangerle, Y. Gevaert, M.F. Fassotte, Y. Beguin, and F. Noizat-Pirenne Direct stimulation of cytokines (IL-1 beta, TNF-alpha, IL-6, IL-2, IFN-gamma and GM-CSF) in whole blood. I. Comparison with isolated PBMC stimulation Cytokines 4 1992 239 248
35. ® against Mycobacterium tuberculosis is highly dependent on the antigen dose PLoS One 4 2009 e5930
36. H1 cells define a correlate of vaccine-mediated protection against Leishmania major Nat Med 13 2007 843 850
37. T. Lindenstrom, E.M. Agger, K.S. Korsholm, P.A. Darrah, C. Aagaard, and R.A. Seder Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells J Immunol 182 2009 8047 8055
38. E.K. Forbes, C. Sander, E. Ronan, H. McShane, A.V.S. Hill, and P.C.L. Beverley The presence of multifunctional, high-cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice J Immunol 181 2008 4955 4964